EOCN
Galmed Pharmaceuticals Ltd.
There isn't enough reported data to score EOCN yet.
EOCN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
EOCN's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
EOCN PE Valuation
EOCN has no meaningful PE right now: it lost money over the past year.
EOCN Forward outlook
There aren't enough analyst estimates for EOCN to show an outlook.
EOCN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q4 2023 | -$240.00 | +$782.40 |
| Q4 2022 | -$1,022.40 | +$878.40 |
| Q4 2021 | -$1,900.80 | +$50.81 |
| Q4 2020 | -$1,951.61 | -$555.87 |
| Q2 2020 | -$1,661.92 | -$768.77 |
| Q4 2019 | -$1,395.74 | -$535.77 |
| Q2 2019 | -$893.15 | +$339.67 |
| Q4 2018 | -$859.97 | +$575.82 |
EOCN is still losing money, but far less than before: $240.00 per share over the past year, against $2,146.20 at its worst in late 2016.
EOCN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2018 | $1.5M | +174% |
| Q2 2018 | $538K | 0% |
| Q4 2017 | $547K | +17% |
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2018 | -306% | +3302 points |
| Q2 2018 | -965% | N/A |
| Q4 2017 | -1178% | N/A |
| Q2 2017 | -1088% | N/A |
| Q4 2016 | -3607% | N/A |
EOCN's operating margin was −306% last quarter, up 3301 points from the same quarter a year ago.
EOCN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2022 | -$18.5M | +$14.4M |
| Q2 2022 | -$11.4M | +$5.6M |
| Q4 2021 | -$32.9M | -$19.4M |
| Q2 2021 | -$16.9M | -$4.1M |
| Q4 2020 | -$13.5M | -$5.5M |
| Q2 2020 | -$12.8M | -$5.8M |
| Q4 2019 | -$7.9M | -$3.7M |
| Q2 2019 | -$7M | -$2.1M |
EOCN has burned cash in almost every quarter: −$80M over the past year, against −$41M the year before.
EOCN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +65% | +350K shares |
| 1 year | +1351% | +828K shares |
| 3 years | +5951% | +874K shares |
| 5 years | +11429% | +881K shares |
EOCN has 888,762 diluted shares, up 1351% from a year ago.
EOCN Net Leverage
EOCN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
EOCN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 16.2 | Oversold |
EOCN's weekly RSI is 31 (neutral) and its Stochastic is 16 (oversold).
EOCN PE vs Healthcare Sector
EOCN has no meaningful PE right now: it lost money over the past year.
EOCN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.11 | 23% below |
| 20 week MA | $3.80 | 37% below |
| 50 week MA | $4.86 | 51% below |
| 100 week MA | $9.57 | 75% below |
| 200 week MA | $94.9 | 97% below |
EOCN is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
EOCN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8,222.4 | $5,184.0 | -37% |
| 2021 | $5,184.0 | $2,923.2 | -44% |
| 2022 | $2,923.2 | $774.3 | -74% |
| 2023 | $774.3 | $43.7 | -94% |
| 2024 | $43.7 | $25.0 | -43% |
| 2025 | $25.0 | $6.92 | -72% |
| 2026 YTD | $6.92 | $2.39 | -65% |
EOCN has finished every year since 2020 lower, and it's down 65% so far in 2026.